Mid cap infrastructure construction stock Chicago Bridge & Iron Company N.V. (NYSE: CBI) fell 7.23% after being trashed in an article by an apparent�short seller posted on Seeking Alpha, meaning its worth taking a closer look at the stock along with the performance of potential benchmarks like Jacobs Engineering Group Inc (NYSE: JEC), KBR, Inc (NYSE: KBR) and First Trust ISE Global Engineering and Construction Index Fund ETF (NYSEARCA: FLM).
What is the Chicago Bridge & Iron Company N.V.?Founded in 1889 in Chicago, mid cap Chicago Bridge & Iron Company N.V. calls itself the most complete energy infrastructure focused company in the world and a major provider of government services. In fact, Chicago Bridge & Iron Company N.V. is one of the most complete providers of a wide range of services including design, engineering, construction, fabrication, maintenance and environmental services.
Hot Net Payout Yield Companies To Own For 2015: El Paso Pipeline Partners LP (EPB)
El Paso Pipeline Partners, L.P. engages in the ownership and operation of natural gas transportation pipelines and storage assets in the United States. The company holds a 100% interest in Wyoming Interstate Company, Ltd. (WIC), an interstate pipeline transportation company located in Wyoming, Utah, and Colorado. It operates approximately 800-mile WIC interstate natural gas pipeline system with a design capacity of approximately 3.5 billion cubic feet per day. The company also owns a 58% general partner interest in Colorado Interstate Gas Company, which operates an interstate natural gas pipeline system with approximately 4,300 miles of pipeline with a design capacity of approximately 4.6 billion cubic feet per day; and associated storage facilities with 37 billion cubic feet of underground working natural gas storage capacity. In addition, it owns a 60% general partner interest in Southern Natural Gas Company that operates an interstate natural gas pipeline system with ap proximately 7,600 miles of pipeline with a design capacity of approximately 3.7 billion cubic feet per day; and associated storage facilities with a total of approximately 60 billion cubic feet of underground working natural gas storage capacity. Further, the company owns interests in Elba Express Company, L.L.C., which operates an approximately 200-mile pipeline with a design capacity of 945 million cubic feet per day; and Southern LNG Company, L.L.C. that owns a liquefied natural gas receiving terminal with a storage capacity of 11.5 equivalent billion cubic feet. It serves natural gas distribution and industrial companies, electric generation companies, natural gas producers, other natural gas pipeline companies, and natural gas marketing and trading companies. El Paso Pipeline GP Company, L.L.C. serves as the general partner of the company. The company was founded in 2007 and is based in Houston, Texas. El Paso Pipeline Partners, L.P. is a subsidiary of El Paso Pipeline LP Holdings, L.L.C.
Advisors' Opinion:- [By David Dittman]
Question: What�� your medium- and long-term outlook for El Paso Pipeline Partners LP (NYSE: EPB), Energy Transfer Partners LP (NYSE: ETP) and Spectra Energy Partners LP (NYSE: SEP)? If you had to choose one for the long term, which one would it be?
- [By David Dittman]
Question: If an investor has a long term outlook, would you consider El Paso Pipeline Partners LP (NYSE: EPB) at current prices to be a good value or does the risk of trying to catch a falling knife outweigh the benefits? At what price would you consider it to be an excellent value play given its projected flat distribution through 2016? How likely is a distribution cut prior to re-establishing distribution growth in 2017?
Top Mid Cap Stocks To Watch Right Now: Oncothyreon Inc .(ONTY)
Oncothyreon Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in two phase III clinical trials for the treatment of non-small cell lung cancer. The company is also developing PX-866, a small molecule that is in phase II trials for various cancer indications. In addition, it engages in the preclinical development of ONT-10, a cancer vaccine; and ONT-701, a pan-inhibitor of the B-cell lymphoma-2 family of anti-apoptotic proteins. The company operates primarily in the United States and Canada. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.
Advisors' Opinion:- [By Lauren Pollock]
Among the companies with shares expected to actively trade in Wednesday’s session are Mako Surgical Corp.(MAKO), Ascena Retail Group Inc.(ASNA) and Oncothyreon Inc.(ONTY)
- [By Ant贸nio Costa]
Oncothyreon Inc (NASDAQ: ONTY) is firming just above key support at $1.78 and a triangle has taken shape over the last few weeks. The stock is starting to show signs of accumulation with high upside days and low downside days. This stock is poised for a move and I suspect that it will explode to the upside. In addition, Inside trading has been very active over the last month. They are buying now after pausing years.
- [By Roberto Pedone]
One under-$10 biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Oncothyreon (ONTY), which develops and markets synthetic vaccines and small molecules that treat cancer patients. This stock hasn't done much so far in 2013, with shares down modestly by 3.9%.
If you take a look at the chart for Oncothyreon, you'll notice that this stock has been trending sideways inside of a consolidation chart pattern for the last month and change, with shares moving between $1.63 on the downside and $1.95 on the upside. Shares of ONTY have been finding some buying interest of late right above its 50-day moving average of $1.73 a share. This stock is now starting to push within range of triggering a big breakout trade above the upper-end of its recent sideways trading chart pattern.
Traders should now look for long-biased trades in ONTY if it manages to break out above some near-term overhead resistance levels at $1.93 to $1.95 a share and then once it takes out more resistance at $1.98 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 689,364 shares. If that breakout triggers soon, then ONTY will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day moving average of $2.12 a share to $2.70 a share.
Traders can look to buy ONTY off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $1.73 a share or around more support at $1.63 a share. One can also buy ONTY off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By James E. Brumley]
On paper, Oncothyreon Inc. (NASDAQ:ONTY) doesn't look like a particularly compelling investment. The pre-revenue biotech company is poised to keep booking sizable losses as it continues to work on its lung cancer drug tecemotide (formerly Stimuvax), which has rejected by the FDA last year but is still being reworked for a slightly different illness than was being targeted initially. And, with no other Phase 3 drug in its pipeline, traders may be rightfully wondering if there's any real catalyst for ONTY in the foreseeable future.
Top Mid Cap Stocks To Watch Right Now: Opus International Consultants Ltd (OIC)
Opus International Consultants Limited is a supplier of multidisciplinary consultancy and project management services across a range of disciplines including, civil, mechanical and electrical engineering, and planning, environmental, architectural and property management. The Company operates in four segments: New Zealand, United Kingdom, Australia and Canada. Services supplied support asset development and asset management activities of the Company�� clients. Asset management services include property management and asset maintenance services predominantly using our engineering and environmental specialists. Asset development services include civil, mechanical and electrical engineering, planning, environmental and architectural work. Effective September 3, 2013, Opus International Consultants Ltda majority-owned unit of Opus Group Bhd acquired Stewart, Weir & Co Ltd. Advisors' Opinion:- [By John McCamant]
Nektar Therapeutics (NKTR) is expected to get FDA approval this year for its lead drug naloxegol, a once-a-day pill for opioid-induced constipation (OIC). The drug is licensed to AstraZeneca. NKTR will receive up to $245 million in milestone payments, plus royalties.
Top Mid Cap Stocks To Watch Right Now: Central Fund of Canada Limited (CEF)
Central Fund of Canada is an closed-ended commodity mutual fund launched and managed by Central Group Alberta, Ltd. It invests in the commodity markets. The fund primarily invests in commodities like silver and gold. Central Fund of Canada was formed on November 15, 1961 and is domiciled in Canada.
Advisors' Opinion:- [By Eric Parnell]
It also remains worthwhile to hedge stock allocations to protect against any major downside event along the way. This includes positions with low correlations such as the PIMCO Total Return ETF (BOND) or the PIMCO Global Advantage Inflation Linked Bond ETF (ILB). This also includes allocations that are likely to rally sharply in the event of a stock pullback but can also continue to rise along with the market such as long-term Treasuries (TLT) or Build America Bonds (BAB). And despite the recent thrashing they have endured, the precious metals complex including gold (GLD), silver (SLV), platinum (PPLT) and palladium (PALL) continue to provide attractive long-term portfolio diversification benefits. I remain long all of these metals via the Central GoldTrust (GTU), the Central Fund of America (CEF), the Sprott Physical Silver Trust (PSLV) and the Sprott Physical Platinum and Palladium Trust (SPPP).
No comments:
Post a Comment